Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 2/20 | 0.57 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | SELL | P14151 | 1/20 | 0.46 |
| ▸ | SELP | P16109 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ASPH | Q12797 | 1/20 | 0.44 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.42 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TTR | P02766 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31455903 | 1.00 | ALB (0.57) | ALBCES2CES1SELLSELP | |
| SCHEMBL13315472 | 0.84 | ALB (0.65) | ALBCES2CES1SELLSELP | |
| SCHEMBL30410503 | 0.82 | ALB (0.57) | ALBCES2CES1SELLSELP | |
| SCHEMBL1922498 | 0.82 | ALB (0.57) | ALBCES2CES1SELLSELP | |
| SCHEMBL23501039 | 0.82 | SELL (0.64) | ALBSELLSELPAKR1C2AKR1C1 | |
| SCHEMBL241797 | 0.81 | CES2 (0.70) | ALBCES2CES1SELLSELP | |
| SCHEMBL201107 | 0.80 | DGAT1 (0.47) | ALBCES2CES1KDM4ETSHR | |
| SCHEMBL2601627 | 0.80 | CES2 (0.45) | ALBCES2CES1KDM4ESMN1; SMN2 | |
| SCHEMBL30548341 | 0.80 | CYP1A2 (0.58) | ALBCES2CES1SELLSELP | |
| SCHEMBL1713540 | 0.80 | CYP1A2 (0.58) | ALBCES2CES1SELLSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9603819-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| US-9603819-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| EP-3048100-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | Novartis AG (CH) | 2016-07-27 | — | — | EP | disclosed |
| EP-2435402-B1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2016-04-13 | — | — | EP | disclosed |
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| US-9006249-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2015-04-14 | — | — | US | disclosed |
| US-9006249-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2015-04-14 | — | — | US | disclosed |
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2012-10-04 | — | — | US | disclosed |
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2012-10-04 | — | — | US | disclosed |
| WO-2010136474-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| CN-101020628-A | Preparation method of 2, 4-difluoro-3-hydroxybenzoic acid | CHEN WEIDONG (CN) | 2007-08-22 | — | — | CN | disclosed |
| CN-101020628-A | Preparation method of 2, 4-difluoro-3-hydroxybenzoic acid | CHEN WEIDONG (CN) | 2007-08-22 | — | — | CN | disclosed |
| EP-0757028-B1 | Process for the preparation of aromatic carbonic acid esters | CLARIANT GMBH (DE) | 1999-12-29 | — | — | EP | disclosed |
| US-5874608-A | Process for the preparation of esters of aromatic carboxylic acid | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-02-23 | — | — | US | disclosed |
| US-5744628-A | Process for the preparation of esters of aromatic carboxylic acids | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-04-28 | — | — | US | disclosed |
| EP-0811601-A1 | Process for the preparation of aromatic carbonic acid esters | Clariant GmbH (DE) | 1997-12-10 | — | — | EP | disclosed |
| EP-0757028-A1 | Process for the preparation of aromatic carbonic acid esters | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | ALB 3916/4885CES2 2140/4885CES1 1107/4885 |
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, GABRB1, GABRE | ALB 3916/4885CES2 2140/4885CES1 1107/4885 |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | ALB 3916/4885CES2 2140/4885CES1 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.